Patient Education on Dulaglutide Medical Injection
Dulaglutide is an injectibale diabetic medicine useful for patients with diabetes types 2. Considering Christina’s history of diabetes, it is advisable to use dulaglutide to control the blood sugar levels. The drug is also used together with good diet and vigorous excise. Christina had already started some exercises, thus, the drug would be more efficient in treating is diabetic condition. However, it is important for Christina to be aware of some of the restrictions and limitations towards the usage of dulaglutide (Reaney & Gwaltney, 2014). Christina should reveal any information related to the history of pancreatitis, stomach disorders, kidney diseases, or any past usage of insulin. These issues should be revealed to the medical physician in order to avoid adverse effects from the usage of dulaglutide.
Christina should follow all guidelines for sale and effective use of dulaglutide. Dulaglutide can be injected under the skin. However, it is not advisable to set inject the medicine and the needles and syringes should be disposed of properly after injection. Dulaglutide is one used once a week. When injecting, the parent should select difference places including the stomach, thigh or upper arm. However, the care provider should provide additional guidelines on how to inject the medication (Wysham et al., 2014). Christina should also monitor closely her low blood sugar levels. Low blood sugar levels occur to everyone who is diagnosed with diabetes. Some of the symptoms include headache, sweating, confusion and dizziness. On the other hand, it is also necessary to monitor the cases of high blood sugar levels including increased thirst and urination, dry skin and blurred vision.
Other cautions when using dulaglutide includes restrictions on the changes to the medication drug. In the case of Christina, she should not change the medication does or schedule except clear guidelines from the doctor (Edwards & Minze, 2015). Secondly, the prefilled syringe should only be used once. Since, the reusage of syringe could affect the dose of the patents. Most importantly, the state and local regulations requires that all syringe to be thrown away after usage. Finally, dulaglutide medicine should not be stored in a refrigerator, as all frozen dulaglutide is unusable.
The possible side effects of dulaglutide can be identified through a summary of the various allergic reactions to the medicine including hives and lips. Signs of pancreatitis are a major side effect resulting from the injection of dulaglutide medicine. This includes increased pains in the upper stomach area, in which later spreads to your back, vomiting, and increased heart rate. A second major sign includes signs of kidney problem such as painful urination, swelling of ankles and feeling tired. Other common side effects of this medicine include loss of appetite, nausea and indigestion (Edwards & Minze, 2015). During the usage of dulaglutide, if Christina encounterssuch side effects, it is recommendable to seek medical advice from a doctor.
In clinical trials, dulaglutida has been used alone or incorporation with other medicine and insulin including metformin. FDA regulations warn patients and other patients about serious concerns associated with therapy and thyroid tumors. FDA recommends a dosage of 0.75mg once a week. FDA also recommends regular risk evaluation and mitigation strategy to educate the patients on the risks of Dulaglutide (American Diabetes Association, 2015). There should also be an effective communication plan to educate healthcare providers about the serious problems related with drug usage. Therefore, Christina should be aware and cautious of the guidelines of medical drugs and insulin.
American Diabetes Association. (2015). Practical insulin: A handbook for prescribing providers. San Jose, CA: American Diabetes Association.
Edwards, K. L., & Minze, M. G. (2015). Dulaglutide: An evidence-based review of its potential in the treatment of type 2 diabetes. Core evidence, 10, 11.
Reaney, M., & Gwaltney, C. (2014). Measuring and interpreting patient-reported outcome data from clinical trials of diabetes medication. Journal of Diabetes Research and Clinical Metabolism, 3(1), 7.
Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., … & Lakshmanan, M. (2014). Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care, 37(8), 2159-2167.